🔗 Share this article

The recently developed medications for gonorrhoea in many years are being hailed as a "significant breakthrough" in the battle against superbug strains of the bacteria, according to health experts.

A Worldwide Challenge

Cases of gonorrhoea are increasing globally, with figures suggesting more than 82 million new cases each year. Notably increased rates are reported in Africa and countries within the WHO's designated area, which spans from Mongolia and China to New Zealand. Within England, cases have hit a historical peak, while infection numbers across Europe in 2023 were three times higher compared to those in 2014.

“The approval of novel therapies for gonorrhoea is an important and timely development in the face of increasing worldwide cases, escalating drug resistance and the highly restricted available drugs currently available.”

Medical experts are particularly alarmed about the increase in antibiotic-resistant strains. The WHO has classified it as a "priority pathogen". A tracking program revealed that resistance to primary antibiotics like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

A Pair of Novel Drugs Receive Approval

Zoliflodacin, marketed under the name a brand name, was cleared by the US Food and Drug Administration in December for combating gonorrhoea. This STI can lead to serious health problems, including the inability to conceive. Researchers believe that specific application of this new drug will help delay the development of resistance.

Gepotidacin, developed by the drugmaker GlaxoSmithKline, gained clearance in close succession. This drug, which is additionally indicated for UTIs, was shown in trials to be effective against drug-resistant strains of the gonorrhoea bacteria.

An Innovative Partnership

This new treatment emerged from a innovative non-profit model for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the drug firm its industry partner to bring it to fruition.

“This approval signifies a significant shift in the management of superbug gonorrhoea, which until now has been staying ahead of our drug pipeline.”

Clinical Trial Results and Global Access

As per findings published in a major medical journal, zoliflodacin eradicated the vast majority of cases of the STI. This places it at an equal footing with the current standard treatment, which uses an injection and a pill. The trial included hundreds of participants from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its unique model, the non-profit has the ability to make available and distribute the drug in numerous regions with limited resources.

Clinicians directly involved have shared positive views. Having a one-pill regimen like this is seen as a "critical tool" for managing the epidemic. This is deemed essential to alleviate the strain of the infection for people and to stop the proliferation of untreatable gonorrhoea around the world.